Cargando…
Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus st...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/ https://www.ncbi.nlm.nih.gov/pubmed/36193094 http://dx.doi.org/10.1155/2022/6432750 |
_version_ | 1784800745665593344 |
---|---|
author | Wang, Shumin Zhang, Meiyi Yu, Leilei Tian, Fengwei Lu, Wenwei Wang, Gang Chen, Wei Wang, Jialin Zhai, Qixiao |
author_facet | Wang, Shumin Zhang, Meiyi Yu, Leilei Tian, Fengwei Lu, Wenwei Wang, Gang Chen, Wei Wang, Jialin Zhai, Qixiao |
author_sort | Wang, Shumin |
collection | PubMed |
description | BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection. METHODS: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. (14)C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial. RESULTS: The (14)C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients. CONCLUSION: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific. |
format | Online Article Text |
id | pubmed-9525740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-95257402022-10-02 Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial Wang, Shumin Zhang, Meiyi Yu, Leilei Tian, Fengwei Lu, Wenwei Wang, Gang Chen, Wei Wang, Jialin Zhai, Qixiao Can J Infect Dis Med Microbiol Research Article BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection. METHODS: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. (14)C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial. RESULTS: The (14)C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients. CONCLUSION: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific. Hindawi 2022-09-23 /pmc/articles/PMC9525740/ /pubmed/36193094 http://dx.doi.org/10.1155/2022/6432750 Text en Copyright © 2022 Shumin Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Shumin Zhang, Meiyi Yu, Leilei Tian, Fengwei Lu, Wenwei Wang, Gang Chen, Wei Wang, Jialin Zhai, Qixiao Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title | Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_full | Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_fullStr | Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_full_unstemmed | Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_short | Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_sort | evaluation of the potential protective effects of lactobacillus strains against helicobacter pylori infection: a randomized, double-blinded, placebo-controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/ https://www.ncbi.nlm.nih.gov/pubmed/36193094 http://dx.doi.org/10.1155/2022/6432750 |
work_keys_str_mv | AT wangshumin evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT zhangmeiyi evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT yuleilei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT tianfengwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT luwenwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT wanggang evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT chenwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT wangjialin evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial AT zhaiqixiao evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial |